Overview

A Phase I/IIa Open-Label, Dose Escalation and Cohort Expansion Trial of Oral TSR-011 in Patients With Advanced Solid Tumors and Lymphomas

Status:
Completed

Trial end date:
2018-06-01

Target enrollment:

Participant gender:

Summary

TSR-011 is a potent small molecule inhibitor of tyrosine kinases involved in cancer, including: 1. Anaplastic lymphoma kinase (ALK) 2. The tropomyosin-related kinases TRKA, TRKB, and TRKC This is a sequential, open-label, non-randomized study with dose escalation in Phase 1, followed by expansion at a recommended phase 2 dose.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Tesaro, Inc.

Treatments:

Belizatinib